The firm owns a Beta (Systematic Risk) of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Q BioMed are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Q BioMed has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Q BioMed is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
QBIO
Q BioMed Relative Risk vs. Return Landscape
If you would invest 0.01 in Q BioMed on December 2, 2025 and sell it today you would earn a total of 0.00 from holding Q BioMed or generate 0.0% return on investment over 90 days. Q BioMed is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than QBIO, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Q BioMed Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Q BioMed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Q BioMed can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Q BioMed generated a negative expected return over the last 90 days
Q BioMed has some characteristics of a very speculative penny stock
Q BioMed has a very high chance of going through financial distress in the upcoming years
Q BioMed currently holds 3.42 M in liabilities with Debt to Equity (D/E) ratio of 0.71, which is about average as compared to similar companies. Q BioMed has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Q BioMed until it has trouble settling it off, either with new capital or with free cash flow. So, Q BioMed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Q BioMed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for QBIO to invest in growth at high rates of return. When we think about Q BioMed's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 195.6 K. Net Loss for the year was (8.24 M) with loss before overhead, payroll, taxes, and interest of (51.25 K).
Q BioMed currently holds about 27.17 K in cash with (4.3 M) of positive cash flow from operations.
Q BioMed Fundamentals Growth
QBIO Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Q BioMed, and Q BioMed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on QBIO Pink Sheet performance.
By examining Q BioMed's fundamental ratios, stakeholders can obtain critical insights into Q BioMed's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Q BioMed is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. Q Biomed operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Things to note about Q BioMed performance evaluation
Checking the ongoing alerts about Q BioMed for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Q BioMed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Q BioMed generated a negative expected return over the last 90 days
Q BioMed has some characteristics of a very speculative penny stock
Q BioMed has a very high chance of going through financial distress in the upcoming years
Q BioMed currently holds 3.42 M in liabilities with Debt to Equity (D/E) ratio of 0.71, which is about average as compared to similar companies. Q BioMed has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Q BioMed until it has trouble settling it off, either with new capital or with free cash flow. So, Q BioMed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Q BioMed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for QBIO to invest in growth at high rates of return. When we think about Q BioMed's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 195.6 K. Net Loss for the year was (8.24 M) with loss before overhead, payroll, taxes, and interest of (51.25 K).
Q BioMed currently holds about 27.17 K in cash with (4.3 M) of positive cash flow from operations.
Evaluating Q BioMed's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Q BioMed's pink sheet performance include:
Analyzing Q BioMed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Q BioMed's stock is overvalued or undervalued compared to its peers.
Examining Q BioMed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Q BioMed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Q BioMed's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Q BioMed's pink sheet. These opinions can provide insight into Q BioMed's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Q BioMed's pink sheet performance is not an exact science, and many factors can impact Q BioMed's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in QBIO Pink Sheet
Q BioMed financial ratios help investors to determine whether QBIO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in QBIO with respect to the benefits of owning Q BioMed security.